2018 AANS Annual Scientific Meeting-Biomarkers of TBI: Where (and Why) Do We Stand?

Video Transcription

Video Summary

In this video, Professor Andras Buki from Hungary discusses biomarkers and traumatic brain injury (TBI). He highlights the importance of biomarkers in diagnosing, predicting, and assessing the outcome of TBI patients. Professor Buki mentions the success of using biomarkers such as S100 beta and GFAP breakdown products in certain cases. However, he also criticizes the limited availability of sound studies for many biomarkers and the high rate of false positives in some cases. He suggests that future research should focus on real-world clinical questions, use internationally approved reference standards, and combine biomarker panels to enhance predictive power. Professor Buki also mentions the potential use of biomarkers in reducing the target population for clinical trials and the need for handheld devices for quick and easy biomarker testing. He concludes by highlighting the need for further research and the potential for biomarkers to improve patient care in TBI.

Asset Caption

Andras Buki, MD, PhD (Hungary)

Keywords

biomarkers

traumatic brain injury

diagnosis

predictive power

clinical trials